Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

HIKAL. vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 HIKAL.   MYLAN
EQUITY SHARE DATA
    HIKAL.
Mar-23
MYLAN
Dec-18
HIKAL./
MYLAN
5-Yr Chart
Click to enlarge
High Rs4563,975-   
Low Rs2162,188-   
Sales per share (Unadj.) Rs164.11,829.1-  
Earnings per share (Unadj.) Rs6.449.7-  
Cash flow per share (Unadj.) Rs15.2392.1-  
Dividends per share (Unadj.) Rs1.200-  
Avg Dividend yield %0.40-  
Book value per share (Unadj.) Rs91.91,978.8-  
Shares outstanding (eoy) m123.30514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.01.7 121.5%   
Avg P/E ratio x52.862.0 85.2%  
P/CF ratio (eoy) x22.17.9 281.3%  
Price / Book Value ratio x3.71.6 234.7%  
Dividend payout %18.90-   
Avg Mkt Cap Rs m41,4201,585,442 2.6%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m2,2240-   
Avg. sales/employee Rs Th026,887.8-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0730.1-  
INCOME DATA
Net Sales Rs m20,230941,074 2.1%  
Other income Rs m540-   
Total revenues Rs m20,284941,074 2.2%   
Gross profit Rs m2,571243,515 1.1%  
Depreciation Rs m1,090176,206 0.6%   
Interest Rs m48145,262 1.1%   
Profit before tax Rs m1,05422,047 4.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m270-3,507 -7.7%   
Profit after tax Rs m78425,554 3.1%  
Gross profit margin %12.725.9 49.1%  
Effective tax rate %25.6-15.9 -161.0%   
Net profit margin %3.92.7 142.7%  
BALANCE SHEET DATA
Current assets Rs m9,683525,495 1.8%   
Current liabilities Rs m6,908383,144 1.8%   
Net working cap to sales %13.715.1 90.7%  
Current ratio x1.41.4 102.2%  
Inventory Days Days2684 30.6%  
Debtors Days Days8093 85.4%  
Net fixed assets Rs m15,024182,553 8.2%   
Share capital Rs m247501 49.2%   
"Free" reserves Rs m11,0880-   
Net worth Rs m11,3351,018,070 1.1%   
Long term debt Rs m4,8991,098,825 0.4%   
Total assets Rs m24,7072,730,861 0.9%  
Interest coverage x3.21.5 214.5%   
Debt to equity ratio x0.41.1 40.0%  
Sales to assets ratio x0.80.3 237.6%   
Return on assets %5.12.6 197.4%  
Return on equity %6.92.5 275.5%  
Return on capital %9.53.2 297.3%  
Exports to sales %67.60-   
Imports to sales %25.60-   
Net fx Rs m8,5000-   
CASH FLOW
From Operations Rs m3,153195,555 1.6%  
From Investments Rs m-2,923-101,081 2.9%  
From Financial Activity Rs m-77-91,101 0.1%  
Net Cashflow Rs m1531,620 9.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare HIKAL. With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare HIKAL. With: VIVO BIO TECH  PANACEA BIOTECH  ADLINE CHEM LAB  RPG LIFE SCIENCES  VALIANT LABORATORIES LTD.  



Today's Market

Sensex Today Tanks 500 Points Amid Iran-Israel Tensions | Nifty Below 21,850 | All Sectors in Red Sensex Today Tanks 500 Points Amid Iran-Israel Tensions | Nifty Below 21,850 | All Sectors in Red(10:30 am)

Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.